Facebook Pixel

Choosing Best Ovarian Cancer Drug May Be Aided by Genetics

By HERWriter
Rate This
Choice of Best Ovarian Cancer Drug May Be Aided by Genetics Divakaran Dileep/PhotoSpin

Research suggests that genetic testing may one day help doctors choose the most effective drug to treat an individual woman’s ovarian cancer. Researchers at the University of Colorado Cancer Center and University of Virginia reported their findings in the journal PloS ONE.

Ovarian cancer that starts in a woman’s ovaries. Women have two ovaries located on each side of the uterus in the abdomen. The ovaries produce eggs and release the hormones estrogen and progesterone.

The American Cancer Society estimates that nearly 22,000 new cases of ovarian cancer will be diagnosed in 2014, and over 14,000 women will die from the disease this year. Ovarian cancer ranks fifth overall in cancer deaths for women, but is the most deadly of all women’s reproductive cancers.

Currently there is no test for early detection of ovarian cancer. This means ovarian cancer is often not diagnosed until it has spread into the pelvis or abdomen, making it much more difficult to treat.

Three drugs are commonly used to treat ovarian cancer: paclitaxel, cyclophosphamide and topotecan. According to the research teams in Virginia and Colorado, the odds of choosing the best of these drugs to treat a specific woman’s cancer can be significantly increased using genetic testing.

The scientists studied tumor samples from four groups of 783 patients who had been treated for ovarian cancer. The method known as CO-eXpression gENe analysis (COXEN) allowed them to examine and sort data from thousands of tumor samples to uncover differences between tumors that responded to each of the three drugs.

Using this information, they were able to select what would have been the best drug treatment for each patient in the study, and compare that information to the actual treatment the patients had received.

"The model allowed us to ask what would have been the right drug in each case, how could we have known from the tumor's genetics and what difference it made," said Jennifer R. Diamond, MD, CU Cancer Center investigator and medical oncologist at the University of Colorado Hospital.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Ovarian Cancer

Get Email Updates

Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!